The following have occurred in a few cases: Skin: Photosensitivity, erythema multiforme, alopecia.
Central and peripheral nervous system: Arthralgia, muscular weakness, myalgia, reversible mental confusion, agitation, depression and hallucinations, mostly in severely ill patients.
Gastrointestinal: Dry mouth, stomatitis and gastrointestinal candidiasis.
Hepatic: Encephalopathy in patients with pre-existing severe liver disease; hepatitis with or without jaundice, hepatic failure. Increases in liver enzymes have been observed.
Endocrine: Gynaecomastia.
Haematologic: Leukopenia and thrombocytopenia.
Other: Hypersensitivity reactions, e.g. urticaria, angioedema, fever, bronchospasm and interstitial nephritis. Increased sweating, peripheral oedema, blurred vision and taste disturbance.
Other effects related to acid inhibition: During long-term treatment gastric glandular cysts have been reported to occur more frequently. These changes are benign and seem to be reversible and area physiological consequence of pronounced inhibition of acid secretion.
If a gastric ulcer is suspected, the possibility of malignancy should be excluded as treatment may mask the symptoms and delay diagnosis.
View ADR Monitoring Form